Results 1 to 10 of about 19,967 (214)

Emerging carbapenemases: a global perspective

International Journal of Antimicrobial Agents, 2010
The celestial rise in antibiotic resistance among Gram-negative bacteria has challenged both the scientific and pharmaceutical sectors. The hallmark of this general increase is the unbridled dissemination of carbapenem resistance genes, namely KPC, OXA and metallo-β-lactamase variants.
Timothy R. Walsh
openalex   +4 more sources

P-1337. Trends in the co-carriage of multiple carbapenemases among clinical Enterobacterales isolates and the in vitro activity of aztreonam-avibactam, ATLAS 2019-2023 [PDF]

Open Forum Infect Dis
Mark Estabrook, Julie Dickson, Gregory Stone, Katherine K. Perez, D.F. Sahm   +4 more
europepmc   +3 more sources

Carriage of K. pneumoniae and molecular structure of produced carbapenemases in infants with congenital heart defects [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2023
Objective. To evaluate frequency of pharyngeal and rectal mucosa colonization by K. pneumoniae strains in infants with congenital heart defects at the stage of cardiosurgical hospital admission, as well as dynamic analysis of production frequency and ...
Popov D.A., Osokina R.A., Vostrikova T.Yu.   +2 more
doaj   +1 more source

Expression analysis of drug-resistant gene (blaOXA-51) in carbapenemases producing Acinetobacter baumannii treated with imipenem/sulbactam combination

Brazilian Journal of Pharmaceutical Sciences, 2021
Drug-resistant Acinetobacter baumannii is a frightening reality. The aim of this study is to examine the expression profiles of blaOXA-51 gene in carbapenemases producing A. baumannii treated with imipenem/sulbactam combination.
Saber Noshadi, Alireza Khodavandi
doaj   +1 more source

Evaluation of Xpert Carba-R for detecting carbapenemase-producing organisms in South Africa

African Journal of Laboratory Medicine, 2023
This study evaluated the performance of the Xpert Carba-R assay for detecting the five common carbapenemases in carbapenemase-producing organisms in Johannesburg, South Africa between April 2021 and September 2021.
Sanelisiwe T. Duze, Teena Thomas, Tshegofatso Pelego, Sabelle Jallow, Olga Perovic, Adriano Duse   +5 more
doaj   +1 more source

Carbapenemases as factors of Resistance to Antibacterial Drugs

Acta Biomedica Scientifica, 2021
Antibiotic drugs are used to treat and prevent bacterial infections around the world. The emergence and spread of  bacterial resistance to carbapenems is currently a real threat that determines the need for its timely detection and  suppression ...
A. V. Nevezhina
doaj   +1 more source

Genetic Diversity, Biochemical Properties, and Detection Methods of Minor Carbapenemases in Enterobacterales

Frontiers in Medicine, 2021
Gram-negative bacteria, especially Enterobacterales, have emerged as major players in antimicrobial resistance worldwide. Resistance may affect all major classes of anti-gram-negative agents, becoming multidrug resistant or even pan-drug resistant ...
Rémy A. Bonnin, Rémy A. Bonnin, Rémy A. Bonnin, Agnès B. Jousset, Agnès B. Jousset, Agnès B. Jousset, Agnès B. Jousset, Cécile Emeraud, Cécile Emeraud, Cécile Emeraud, Cécile Emeraud, Saoussen Oueslati, Saoussen Oueslati, Laurent Dortet, Laurent Dortet, Laurent Dortet, Laurent Dortet, Thierry Naas, Thierry Naas, Thierry Naas, Thierry Naas   +20 more
doaj   +1 more source

Comparative Activity of Carbapenem Antibiotics Against Gram-Negative Carbapenemase Producers of Different Groups

Антибиотики и Химиотерапия, 2022
The rapid spread of gram-negative bacteria resistance to carbapenems due to the production of carbapenemases requires new treatment options. The activity of carbapenem antibiotic biapenem, recently registered in Russia, against producers of various ...
V. A. Ageevets, O. S. Sulian, A. A. Avdeeva, P. S. Chulkova, V. V. Gostev, I. V. Ageevets, M. V. Golikova, K. N. Alieva, D. P. Gladin, S. V. Sidorenko   +9 more
doaj   +1 more source

Class A carbapenemases [PDF]

Journal of Antimicrobial Chemotherapy, 2007
Carbapenems, such as imipenem and meropenem, are most often used to treat infections caused by enterobacteria that produce extended-spectrum beta-lactamases, and the emergence of enzymes capable of inactivating carbapenems would therefore limit the options for treatment.
Walther-Rasmussen, J., Høiby, N.
openaire   +2 more sources

In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018

Journal of Global Antimicrobial Resistance, 2021
: Objectives: This study reports the antimicrobial activity of ceftazidime/avibactam (CZA) and comparators against carbapenemase-producing Enterobacterales (N = 1992) and carbapenemase-producing Pseudomonas aeruginosa (N = 784) collected in Africa/Middle
Pattarachai Kiratisin, Krystyna Kazmierczak, Gregory G. Stone   +2 more
doaj   +1 more source